TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06639087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD5462
Description: Participants will receive AZD5462 on top of dapagliflozin once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin once daily with AZD5462 or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin once daily with AZD5462 or placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo on top of dapagliflozin once daily.
Study: NCT06644131

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Creatine Monohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (Placebo)
Description: Placebo - sugar pill
Study: NCT05371379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM338 Injection
Description: A humanized monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM338 Injection
Description: A humanized monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM338 Injection
Description: A humanized monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM338 Injection
Description: A humanized monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CM338 Injection
Description: A humanized monoclonal antibody.
Study: NCT06643572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality simulator
Description: This virtual reality simulator allows for the simulation of a lumbar transforaminal epidural steroid injection using the patient's 3D lumbar images.
Study: NCT04892277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo CT/PET
Study: NCT05963984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samuraciclib
Description: Samuraciclib tablet by mouth once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samuraciclib
Description: Samuraciclib tablet by mouth once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15
Study: NCT05078112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep sensor technology
Description: Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output to soothe them to sleep. The device will give this output for first 10 nights, then wean the output the child receives over 10 nights.
Study: NCT05645380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=6, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=6, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=6, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg, IV
Study: NCT04558736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (Rabbit)
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days, or as clinically indicated

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Description: TLI will be given at 800 cGy total dose in 4 fractions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC, A Infusion
Description: Given intravenously Day 0-HPC, A Infusion (TCR αβ+/CD19+-depleted graft)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD45RA-depleted DLI
Description: CD45RA-depleted DLI will be given at least ONE week after engraftment
Study: NCT06567548

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: An absorbable gelatin sponge is a sterile hemostatic agent primarily composed of purified porcine-derived gelatin. It is widely utilized in surgical procedures to control bleeding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich fibrin (PRF)
Description: Platelet-rich fibrin (PRF) is a biomaterial derived from the patient's own blood, utilized primarily in regenerative medicine and surgery due to its rich content of growth factors and its ability to promote healing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Albumin Platelet Rich- Fibrin
Description: is an innovative biomaterial that combines the regenerative properties of platelet-rich fibrin (PRF) with the structural and functional benefits of albumin. This mixture is designed to enhance tissue healing and regeneration by utilizing autologous blood components.
Study: NCT05052684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leaflex™ Performer
Description: A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
Study: NCT06529484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Water Foot Bath Intervention
Description: Participants will take a warm water foot bath at 38-40ºC for 20 minutes nightly for 7 days.
Study: NCT06122948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The midazolam group
Description: The midazolam group will receive intranasal midazolam (0.1 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The midazolam ketamine group
Description: the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
Study: NCT06187909

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS II BLOCK
Description: The linear probe will be placed transversely between the clavicle medially and above . After identifying the pectoralis major and minor muscles , the probe will be angled caudally to look for the pulsating pectoral branch of the thoraco-acromial artery. The block needle will be inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine will be administered. Then probe will be moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The third and fourth ribs will be detected. The needle will target the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 20 ml bupivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTP BLOCK
Description: The block will be performed with the patient in a sitting position ,High frequency linear probe will be placed in a vertical orientation 3 cm lateral to the midline at T2 level in parasagittal plane. We will identify the midpoint between the transverse process and parietal pleura, and the distance from this point to the skin will be measured which will be the measured depth of insertion and will be marked in the block needle. The block needle will be inserted out of plane to the probe and advanced till the marked depth till the point is confirmed, 10 ml of 0.25% bupivacaine will be injected. Similar two injections will be made at T4, T6 levels sonographic identification and level determination by counting from the second rib.
Study: NCT06460532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline treatment
Description: Transcutaneous Electric Nerve Stimulation (TENS) of Care Vision company will be applied, with a pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the suboccipital region and the trapezius bilaterally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline treatment
Description: Transcutaneous Electric Nerve Stimulation (TENS) of Care Vision company will be applied, with a pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the suboccipital region and the trapezius bilaterally.
Study: NCT05765175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Varian Cardiac Radioablation (CRA)
Description: Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation (CA)
Description: Subjects randomized to the CA arm will be treated according to a uniform CA protocol.
Study: NCT05329831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured training using telehealth
Description: The intervention is based on self-care activities. Self-care states that people have an innate ability to take care of themselves.
Study: NCT05456087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxin A
Description: Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area
Study: NCT06570252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: activated Light Source (aPDT)
Description: Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~Activation of SW4000 Light Source (Class 1 Laser Device) that generates red light consisting of 2 channels of 700 mW, 664 nm light (continuous wave) used to activate the disinfecting formulation.~Duration of illumination 2 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non activated Light Source (Control)
Description: Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~No activation of SW4000 Light Source~Waiting for 2 minutes
Study: NCT06570200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PMPR+iPRF
Description: locally applied iPRF in the periodontal pocket

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMPR+iPRF+Vit.D
Description: locally applied iPRF plus vitamin D in the periodontal pocket
Study: NCT05667987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine administration
Description: General anesthesia with intravenous lidocaine administration
Study: NCT06570200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PMPR only
Description: scaling and root planing only will be done for the periodontal pocket for the control group
Study: NCT04416711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback
Description: The personalized feedback consists of four components: normative feedback, risk/protective feedback, decisional balance/goal setting, and protective strategy review. Personalized feedback targets include readiness to change, perceptions of risk, and misperceptions of peer attitudes/behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Skills Training
Description: We will address three cognitive targets: focus on affective cues, focus on non-affective cues, and over-perception of sexual interest. The first module targets enhanced focus on women's affective cues and reduced over-perception of sexual interest. We will introduce the role of men's sexual-perception skills in satisfying social and sexual interactions with women, as well as problematic sexual behavior including RSB and SAB. Next, we will instruct participants that affective information is the best-available nonverbal information about how a woman is feeling about a specific man. This instruction will focus on distinguishing four primary dating relevant cues: sexual-interest, friendliness, sadness, and rejection. More detailed focus on each cue will emphasize the increased difficulty of reading these cues with a new partner and under the influence of alcohol and sexual arousal, as well as the importance of checking verbally on assumptions about a woman's current sexual interest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Services As Usual
Description: These participants will receive services as usual
Study: NCT04648085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal Nerve Stimulation
Description: Applied to to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve.The device generates electrical impulses allowing to stimulate the trigeminal nerve.
Study: NCT05591365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured In-Patient and Home plan
Description: A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Therapy
Description: In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)
Study: NCT05748769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice (UL)
Description: Subjects performed RMs toward the units that were activated in the same order as the tested sequence 1-4-3-5-4-2, and with an activation duration and delay of 1 s. The practice included 16 blocks, each consisting of 30 RM with a 30 s pause after each block

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Observation (SO)
Description: Subjects observed the illuminating switches while avoiding moving. The subjects observed RMs toward the units that were activated in the same order as the practiced sequence 1-4-3-5-4-2, also with an activation duration and delay of 1 s and 30 s pause after each block.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nature Observation (NO)
Description: The video-clip consisted of a 16 min nature movie in cycles of one-minute observation and pausing 30 s, equivalent to the timing of RMs performed by groups UL and SO
Study: NCT06445023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo Subcutaneous Administration
Study: NCT06591455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 200mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA (Ursodeoxycholic acid)
Description: UDCA 13-15mg/kg/day
Study: NCT06608849

Intervention type: OTHER
Intervention: Blood samples
Description: Blood sampling for proteomics and transcriptomics, suPAR measurement \&amp; isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \&amp; urea

Intervention type: OTHER
Intervention: Blood samples
Description: Blood sampling for proteomics and transcriptomics, suPAR measurement \&amp; isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \&amp; urea

Intervention type: OTHER
Intervention: Blood samples
Description: Blood sampling for proteomics and transcriptomics, suPAR measurement \&amp; isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \&amp; urea

Intervention type: OTHER
Intervention: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
Description: Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.

Intervention type: OTHER
Intervention: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
Description: Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.

Intervention type: OTHER
Intervention: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
Description: Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
Study: NCT05576337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16 weeks of strength training protocol
Description: 16 weeks of strength training protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16 weeks of strength training protocol
Description: 16 weeks of strength training protocol
Study: NCT06591741

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral PCA
Description: PCA 1,000 mg BID until surgery, held until anticoagulation, and resumed at 1,000 mg daily for 4 years
Study: NCT06541197

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic rehabilitation combined with Functional Electrical Stimulation (FES) bicycle ergometry group
Description: Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks. For FES bicycle ergometry, a current-controlled six-channel stimulator (RT 300-SLSA; Restorative Therapies, Baltimore, MD, USA) will be used. The quadriceps, hamstring and tibialis anterior muscles will be stimulated bilaterally with six channels through 3 × 4 cm2 adhesive surface electrodes. Stimulation intensity will be adjusted according to palpable muscle contraction and sensory discomfort felt by patients with incomplete SCI. The pedaling cadence range will be set to 40-50 rotations per minute. FES bicycle ergometry will be performed in 30-minute sessions for 4 weeks for a total of 20 sessions before robotic rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic rehabilitation
Description: Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks.
Study: NCT06674564

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Acetate 50 Mg Oral Capsule
Description: zinc suppose to improve immunity and wound healing after laryngectomy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Acetate 50 Mg Oral Capsule
Description: zinc suppose to improve immunity and wound healing after laryngectomy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: probiotics lowering infections rates and improving outcomes after surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: probiotics lowering infections rates and improving outcomes after surgery